Skip to main content

Market Overview

Amgen Shares Drop On Light First Quarter Earnings Hit By Lower Prices

Share:
Amgen Shares Drop On Light First Quarter Earnings Hit By Lower Prices

Amgen Inc (NASDAQ: AMGN) has a rough start this year after its Q1 March-quarter revenue slipped 4% from the year-ago quarter, while its earnings fell about 10%.

Earnings: Even though unit volumes grew 4% in the quarter, the revenue disappointment was primarily tied to lower prices. Net sales prices fell 7%, year over year, the company said.

Revenue was $5.9 billion, compared with the year-ago $6.2 billion, well below the consensus estimate of $6.25 billion. Amgen said new patient starts were hurt because the pandemic kept people from seeing doctors and getting diagnosed.

Amgen’s most significant product, the autoimmune treatment Enbrel, suffered a 20% revenue drop because both the price and volume fell. Another product, Otezla sales decreased 1% on higher volume but at lower prices. The migraine treatment, Aimovig, grew 20% in volume but delivered 7% lower revenue.

The company faces competition from biosimilar versions of some established products. Revenue from white-blood-cell stimulant Neulasta fell 21%, to $482 million, as its average U.S. price slipped 30% Y/Y and 9% sequentially.

Net income fell 10% year over year, to $1.6 billion, or $2.83 a share. Adjusted net income fell 14%, to $2.2 billion, or $3.70 a share, missing consensus of $4.05

Free cash flow (after capital spending) was roughly flat, at $2 billion

Guidance: For 2021, the company expects adjusted earnings as previously guided, at $16 to $17 a share and $25.8 billion to $26.6 billion in sales.

Amgen expects 2021 GAAP net income to fall below $10.70 a share, instead of exceeding $12.12 a share, lower than previous guidance.

The company has increased the share repurchase range from previous guidance of $3.0 billion to $4.0 billion, to $3.0 billion to $5.0 billion.

Additionally, the company agreed with the FDA’s proposed post-marketing requirement to conduct a multi-center randomized clinical trial to compare the safety and efficacy of Lumakras at 960 mg once daily versus 240 mg daily dose.

Lumakras is being evaluated in KRAS G12C-mutant advanced non-small-cell lung cancer. Data from the study is expected in late 2022.

Price Action: AMGN shares are down 3.97% at $245 in the premarket trading on the last check Wednesday.

Image Courtesy: Wikimedia

 

Related Articles (AMGN)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Guidance Health Care Buybacks General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com